Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bristol-Myers Squibb announces new data

Bristol-Myers Squibb announces new data

19th December 2008

Bristol-Myers Squibb has announced new data from phase III breast cancer studies.

The research of the drug Ixempra plus capecitabine – in comparison to capecitabine on its own – involved 2,000 patients.

It also included a pre-specified sub set analysis and demonstrated a “significant increase” in progression free survival in patients with triple negative breast cancer.

Patients in the research were either resistant to or pretreated with anthracyclines and taxanes.

Data found Ixempra plus capecitabine is the first combination regimen to demonstrate statistically significant progression free survival (PFS) compared to capecitabine on its own.

In the triple negative pooled subset analysis, patients who were on the amalgamation had an overall response rate of 31 per cent, in contrast to 15 per cent.

Bristol-Myers Squibb added the PFS of the combination group was a median of 4.2 months, compared to 1.7 months for the singular drug-treated group.

Earlier this week, Bristol-Myers Squibb and Elelixis announced they had entered a global collaboration, covering two novel cancer programmes.

The partnership will see the joint development programmes of Exelixis’ XL184 and XL281.

Under the terms of the collaboration, Bristol-Myers Squibb will pay its partner $195 million (130 million pounds) for the development and commercialisation rights of both projects.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.